SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

SANJIVANI PARANTERAL

BSE: 531569 29 Jun 2025
Healthcare
₹ 220.45
Sanjivani Paranteral Ltd. specializes in Pharmaceuticals within the Healthcare sector.

SANJIVANI PARANTERAL - Share Price & Details

Market Cap
₹256.0
High /Low
397.0 / 190.0
Stock P/E
31.6
Book Value
₹32.0
Dividend Yield
0.0
ROCE
28.5
ROE
₹24.6
Face Value
10.0
PEG Ratio
NA
EVEBITDA
₹22.6
Debt
8.14
CMP / FCF
NA
Debt to equity
₹0.21
NP Ann
8.09
High price all time
397.0
Piotroski score
₹3.0
Graham Number
70.0
No. Eq. Shares
1.19
Net CF
₹0.94
Net profit
8.09
Price to book value
6.73
Interest Coverage
₹18.5
Low price all time
3.17
Industry PE
32.7
Reserves
₹26.1
Free Cash Flow
₹-18.0

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
SANJIVANI PARANTERAL LTD.NANANANA256.031.6
ASARFI HOSPITAL LIMITEDNANANANA25524.1
Aashka Hospitals LimitedNANANANA22991.8

Peer Comparison Chart


About SANJIVANI PARANTERAL

Sanjivani Paranteral Ltd., with Security Code 531569, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Sanjivani Paranteral standalone net profit rises 73.81% in the March 2025 quarter

(31 May 2025)
Sales rise 41.37% to Rs 18.18 crore. Net profit of Sanjivani Paranteral rose 73.81% to Rs 2.19 crore in the quarter ended March 2025 as...
Read more →

Sanjivani Paranteral Reports Strong Financial Growth and Sales Surge in May 2025 Results

(31 May 2025)
Sanjivani Paranteral has announced its financial results for the quarter ending March 2025, revealing a Profit After Tax of Rs 4.09 crore,...
Read more →

Sanjivani Parenteral Adjusts Valuation Grade Amid Competitive Industry Landscape

(30 May 2025)
Sanjivani Parenteral, a microcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, showcasing a price-to-earnings ratio of 35.68...
Read more →

Sanjivani Paranteral Reports Strong Growth Amid Valuation Concerns and Debt Challenges

(29 May 2025)
Sanjivani Paranteral, a microcap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its evaluation, reflecting significant financial...
Read more →

Sanjivani Paranteral consolidated net profit rises 73.81% in the March 2025 quarter

(29 May 2025)
Sales rise 41.37% to Rs 18.18 crore. Net profit of Sanjivani Paranteral rose 73.81% to Rs 2.19 crore in the quarter ended March 2025 as against Rs 1.26...
Read more →

Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr

(28 May 2025)
Sanjivani Paranteral Ltd. reported its results for the quarter & year ended 31st March 2025. The company reported Q4 FY25 Revenue from...
Read more →